Lexaria
Bioscience (CSE: LXX) (OTCQX: LXRP), a global innovator with technology
that has demonstrated its ability to enhance the oral delivery of nicotine, is
positioned to benefit from the FDA’s recent announcement that it had authorized
the marketing of eight smokeless tobacco products through the modified-risk,
tobacco-product (“MRTP”) pathway (http://ibn.fm/3hCAN).
An article discussing the company reads, “The FDA approval of the ‘modified
risk’ claims was made after reviewing scientific evidence submitted by the
manufacturer of the products. The approvals, which are product specific and
expire after five years, do not mean the products come with no health risks.
Nicotine-based products are addictive and may, according to some studies,
induce the onset of cardiovascular, respiratory and gastrointestinal disorders.
. . . The patented DehydraTECH(TM) drug-delivery platform mitigates a serious
limitation to nicotine ingestion. The human GI system struggles to process
nicotine in the forms in which it is presently offered, one reason why there
are currently no edible, nicotine, manufactured products available, although
some natural foods — eggplant, green pepper, potato, tomato — do contain
nicotine. However, DehydraTECH employs a delivery mechanism that improves the
bioabsorption and bioavailability of many ingestible substances, as well as
their taste and smell, by using lipophilic agents. Application of the
technology extends beyond nicotine to nonpsychoactive cannabinoids, vitamins
and nonsteroidal anti-inflammatory drugs (NSAIDs).”
To view the full article, visit http://ibn.fm/Bpse8
About Lexaria Bioscience Corp.
Lexaria Bioscience Corp. is a global innovator in
drug-delivery platforms. Its patented DehydraTECH drug-delivery technology
changes the way active pharmaceutical ingredients enter the bloodstream,
promoting healthier ingestion methods, lower overall dosing and higher
effectiveness for lipophilic active molecules. DehydraTECH increases bioabsorption,
reduces time of onset and masks unwanted tastes for orally administered
bioactive molecules including cannabinoids, vitamins, nonsteroidal
anti-inflammatory drugs (“NSAIDs”), nicotine and other molecules. Lexaria has
licensed DehydraTECH to multiple companies in the cannabis industry for use in
cannabinoid beverages, edibles and oral products, as well as to a world-leading
tobacco producer for the development of smokeless, oral-based nicotine
products. Lexaria operates a licensed, in-house research laboratory and holds a
robust intellectual property portfolio with 16 patents granted and over 60
patents pending worldwide. For more information, visit the company’s website
at www.LexariaBioscience.com.
NOTE TO INVESTORS: The latest news and updates
relating to LXRP are available in the company’s newsroom at http://ibn.fm/LXRP
About MissionIRNewsBreaks
MissionIRNewsBreaks provide
a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by
our Team of professional journalists that keep a constant eye on the markets,
these posts are designed to inform you on the latest happenings of our clients
and other publicly traded companies on our radar. From earnings, acquisitions
and agreements to conference attendance and clinical study results, our news breaks
keep you up-to-date with the day’s top movers. MissionIR is primarily focused
on strategic communications. We have executed countless communications programs
to address the needs of companies ranging from start-ups to established
industry leaders, gaining valuable experience and the expertise necessary to
determine the most effective strategy for any given situation.
Please see full terms of use and disclaimers on the Mission
Investor Relations website applicable to all content provided by MIR, wherever
published or re-published: http://www.missionir.com/disclaimer.html
